Kris DeVault is desperate for his son Brody to try an experimental drug that might help with his rare genetic condition creatine transporter deficiency. Montana’s new ‘right to try’ law could potentially provide access, but the journey is fraught with uncertainty.

Brody’s struggle to communicate and his muscle weakness are stark reminders of the urgency. The experimental drug developed by Ceres Brain Therapeutics has shown promise in mice and healthy adults, but not yet in those with Brody’s condition or children.

Montana’s ETRB is set to review its first applications this week, offering a glimmer of hope for families like DeVault’s. However, the FDA remains hesitant, and alternative routes such as Próspera in Honduras are being considered.

The story highlights the tension between desperate parents, innovative science, and regulatory caution. It’s a reminder that while progress may seem slow, there is always hope for those at the brink of medical innovation.